Merck KGaA (CH:MER)
:MER
MER Stock Chart & Stats
CHF100.00
-CHF102.20(-100.00%)
At close: 4:00 PM EDT
CHF100.00
-CHF102.20(-100.00%)
Day’s Range― - ―
52-Week RangeCHF95.60 - CHF100.00
Previous CloseN/A
Volume19.70K
Average Volume (3M)0.00
Market Cap
CHF54.99B
Enterprise ValueCHF66.19B
Total Cash (Recent Filing)CHF2.74B
Total Debt (Recent Filing)CHF12.04B
Price to Earnings (P/E)23.6
BetaN/A
Next Earnings
Aug 06, 2026EPS Estimate
1.82Next Dividend Ex-DateN/A
Dividend Yield1.79%
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF125.14Price Target Upside25.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.3
Revenue Forecast (FY)CHF19.30B
Bulls Say, Bears Say
Bulls Say
Durable High Margins And Operating ProfitabilityMerck's sustained high gross and operating margins indicate structural pricing power and cost efficiency across segments. Durable margins support internal R&D and capex funding, allow cyclical resilience when revenue softens, and underpin long-term cash generation and reinvestment capacity.
Manageable Leverage And Resilient Balance SheetModerate debt levels and improving leverage provide financial flexibility for strategic investment, M&A or R&D without excessive refinancing risk. A growing equity base strengthens balance-sheet resilience and lowers solvency risk over the medium term.
Diversified, Recurring Revenue Streams Across Three SectorsA three-pronged business model with recurring consumables in Life Science, prescription drugs in Healthcare, and specialty materials in Electronics reduces reliance on any single end market. Diversification smooths cash flows and supports steadier long-term revenue and investment capacity.
Bears Say
Weak Recent Revenue MomentumA flat-to-declining top line constrains scalable margin expansion and reduces available funds for sustained R&D or commercial investment. If revenue weakness persists, it could pressure margins, slow product launches, and limit long-term growth prospects across segments.
Declining Returns On EquityFalling ROE signals less efficient use of capital and weaker profitability against the equity base. Persistently lower returns can indicate challenges in pricing, competition, or capital allocation, reducing the company's ability to generate attractive shareholder returns long term.
Only Moderate Cash Conversion To Free Cash FlowModerate cash conversion limits financial flexibility despite positive FCF. Lower conversion rates reduce capacity to sustain dividends, accelerate R&D or weather prolonged downturns, making long-term investment pacing more dependent on margin and revenue recovery.
MER FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was CHF95.60 and its highest was CHF100.00 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is CHF54.99B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 06, 2026 which is in 57 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 13, 2026. The company reported CHF1.923 earnings per share for the quarter, beating the consensus estimate of CHF1.775 by CHF0.149.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of CHF2.024 which represents an annual dividend yield of 1.79%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 1.82.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of CHF1.923 in its last earnings report, beating expectations of CHF1.775. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in CH:MER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF125.14 (25.14% Upside)
CHF125.14 (25.14% Upside)
Insider Transactions
Bought Shares
Worth CHF752.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.96%
12-Months-Change
Fundamentals
Return on Equity
8.77%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
MER Stock 12 Month Forecast
Average Price Target
CHF125.14
▲(25.14% Upside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---